Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports add new data to breast cancer research
September 8th, 2005
Data on breast cancer are outlined in reports from France, Scotland and Italy. Study 1: Oncologists in France have reported a treatment regimen of adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer was associated with a higher incidence of adverse effects, including febrile neutropenia and one death from sepsis, than the doxorubicin-cyclophosphamide regimen. "Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity," said E.G.C. Brain and colleagues, Rene Huguenin Cancer Center, St. Cloud, France, who described the "adverse events associated with adjuvant chemotherapy for breast...
Source: Women's Health Weekly (2005-09-08)
|
